Beta PRRT → alpha PRRT
When lutetium radioligand therapy stops working, alpha-emitting versions can still control the disease.
Overview
This sequence moves from beta-emitting lutetium-177 dotatate to an alpha-emitting radioligand, 212Pb-DOTAMTATE, when beta PRRT stops controlling a neuroendocrine tumour. Alpha particles deliver oxygen-independent clustered DNA damage that beta-resistant clones cannot repair, so the same somatostatin receptor target can be attacked again with a more destructive payload. The phase 2 ALPHAMEDIX-02 trial included a PRRT-exposed cohort in which disease control was maintained in most patients, and ACTION-1 is the randomised phase 3 test of 225Ac-DOTATATE after 177Lu. The pairing belongs to the wider topic of alpha versus beta emitters and targeted alpha therapy.
Similar pages
not linked directly; found by shared links- RoadmapSSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha
Shares ALPHAMEDIX-02, ACTION-1, 212Pb-DOTAMTATE, Lead-212.
- AgentLead-212 VMT-alpha-NET
Shares 212Pb-DOTAMTATE, Lead-212, Lutetium-177 dotatate, Targeted alpha therapy.
- TermPRRT (peptide receptor radionuclide therapy)
Shares Alpha vs beta emitters, Lead-212, Lutetium-177 dotatate, Targeted alpha therapy.
- PairingBeta radioligand → alpha radioligand
Shares Alpha vs beta emitters, Lutetium-177 dotatate, Targeted alpha therapy, Neuroendocrine tumours.
- TechnologyAlpha-emitter daughter redistribution ('free daughter' problem)
Shares 212Pb-DOTAMTATE, Lead-212, Targeted alpha therapy, Actinium-225.
- TermRelative biological effectiveness (RBE)
Shares Alpha vs beta emitters, Targeted alpha therapy, Actinium-225, Lutetium-177.
- CompanyRadioMedix
Shares 212Pb-DOTAMTATE, Lead-212, Targeted alpha therapy, Neuroendocrine tumours.
- RoadmapAlpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline
Shares ALPHAMEDIX-02, ACTION-1, 212Pb-DOTAMTATE, Lead-212.